Top-Rated StocksTop-Rated Most-Downgraded StocksMost-Downgraded

NASDAQ:BIIB

Biogen (BIIB) Price Target & Analyst Ratings

$251.44

-5.57 (-2.17%)

(As of 01:12 PM ET)

Compare

Today's Range: $251.08
▼
$256.86
50-Day Range: $253.30
▼
$277.00
52-Week Range: $250.31
▼
$319.76

Volume: 365,031 shs
Average Volume: 1.00 million shs
Market Capitalization: $36.41 billion

P/E Ratio: 13.69
Dividend Yield: N/A
Price Target: $327.22

Biogen Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 25 Analyst Ratings

Consensus Analyst Price Target

$327.22
30.14% Upside

High Prediction	$381.00
Average Prediction	$327.22
Low Prediction	$269.00

Type	Current 10/2/22 to 10/2/23	1 Month Ago 9/2/22 to 9/2/23	3 Months Ago 7/4/22 to 7/4/23	1 Year Ago 10/2/21 to 10/2/22
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	21 Buy rating(s)	21 Buy rating(s)	21 Buy rating(s)	15 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	10 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$327.22	$323.70	$330.27	$269.96
Predicted Upside	30.14% Upside	17.39% Upside	20.09% Upside	23.03% Upside

Get Biogen Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

BIIB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Medical Companies	S&P 500
Consensus Rating Score	2.84	2.65	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	30.24% Upside	893.33% Upside	698.25% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$360.00	+35.19%
9/5/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$363.00 ➝ $381.00	+42.61%
8/29/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$354.00 ➝ $357.00	+34.69%
8/14/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$340.00 ➝ $335.00	+22.41%
8/8/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$340.00	+23.73%
8/8/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$347.00 ➝ $336.00	+23.88%
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
8/8/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$282.00 ➝ $275.00	+1.39%
8/8/2023	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$323.00 ➝ $305.00	+12.45%
8/8/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$311.00 ➝ $294.00	+8.40%
8/7/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$350.00 ➝ $343.00	+27.55%
8/7/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$380.00 ➝ $350.00	+30.15%
8/7/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$360.00 ➝ $290.00	+7.84%
8/7/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$310.00 ➝ $290.00	+7.84%
8/7/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$276.00 ➝ $269.00	+0.03%
8/7/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$340.00 ➝ $333.00	+23.83%
7/27/2023	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Outperform	$327.00	+23.28%
7/26/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$325.00	+20.23%
7/25/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$324.00 ➝ $320.00	+20.47%
7/24/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$346.00 ➝ $335.00	+20.79%
5/11/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$320.00 ➝ $350.00	+11.73%
5/1/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$270.00 ➝ $350.00	+15.04%
2/16/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$300.00 ➝ $315.00	+12.91%
12/1/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$370.00	+22.16%
11/30/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$325.00 ➝ $350.00	+20.11%
10/26/2022	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sumant Kulkarni Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$285.00 ➝ $325.00	+16.46%
10/26/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$270.00 ➝ $300.00	+6.36%
10/26/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$270.00 ➝ $310.00	+13.32%

(Data available from 10/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

BIIB Price Target - Frequently Asked Questions

What is Biogen's consensus rating and price target?: According to the issued ratings of 25 analysts in the last year, the consensus rating for Biogen stock is Moderate Buy based on the current 4 hold ratings and 21 buy ratings for BIIB. The average twelve-month price prediction for Biogen is $327.22 with a high price target of $381.00 and a low price target of $269.00. Learn more on BIIB's analyst rating history.
Do Wall Street analysts like Biogen more than its competitors?: Analysts like Biogen more than other Medical companies. The consensus rating score for Biogen is 2.84 while the average consensus rating score for medical companies is 2.66. Learn more on how BIIB compares to other companies.
Does Biogen's stock price have much upside?: According to analysts, Biogen's stock has a predicted upside of 18.26% based on their 12-month price targets.

What analysts cover Biogen?: Biogen has been rated by Atlantic Securities, Bank of America, Barclays, BMO Capital Markets, HC Wainwright, HSBC, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, Truist Financial, UBS Group, Wedbush, and Wells Fargo & Company in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:BIIB) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial